StockUS listing USCRBUNASDAQHealthcareEarnings Deterioration

Caribou Biosciences Inc(CRBU) Stock Analysis | Healthcare

USD --+0.00%
Reward42Moderate
Risk76High
75%Data
Revenue down 27% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 30.71M
Reward Ratingⓘ42 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ76 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CRBU to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Caribou Biosciences Inc?

operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.

AI Brief Pro

The brief on Caribou Biosciences Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Caribou Biosciences Inc?

operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 30.71M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (42)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.488
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
524,317 shares
$47k
0
9-12months
0
0